Sanofi buys French biotechFovea Pharmaceuticals, a French research and development biopharmaceutical company focused on ocular diseases, has been sold by its venture capital backers.
French VC Sofinnova Partners alongside UK life sciences firm Abingworth, the Wellcome Trust, GIMV, Forbion Capital Partners and Crédit Agricole Private Equity, have all sold their stakes to pharmaceutical giant Sanofi-Aventis in a €370m deal.
Founded in 2005, Fovea has a portfolio of three clinical compounds, a technology platform and several discovery programs dedicated to back of the eye diseases.
It raised €20.5m of venture capital money in November the same year in a series A round led by Sofinnova before raising a €30m series B round in December 2007 led by Forbion, the former ABN AMRO Capital Life Sciences team.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: